Literature DB >> 1552217

Natural immunity to shigellosis in two groups with different previous risks of exposure to Shigella is only partly expressed by serum antibodies to lipopolysaccharide.

D Cohen, M S Green, C Block, R Slepon, Y Lerman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1552217     DOI： 10.1093/infdis/165.4.785

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  19 in total

Review 1.  Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road.

Authors:  Myron M Levine; Karen L Kotloff; Eileen M Barry; Marcela F Pasetti; Marcelo B Sztein
Journal:  Nat Rev Microbiol       Date:  2007-07       Impact factor: 60.633

2.  Local immune response and protection in the guinea pig keratoconjunctivitis model following immunization with Shigella vaccines.

Authors:  A B Hartman; L L Van de Verg; H H Collins; D B Tang; N O Bendiuk; D N Taylor; C J Powell
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

3.  Specificity of monoclonal antibodies elicited by mucosal infection of BALB/c mice with virulent Shigella flexneri 2a.

Authors:  A B Hartman; L L Van de Verg; C R Mainhart; B D Tall; S J Smith-Gill
Journal:  Clin Diagn Lab Immunol       Date:  1996-09

4.  Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults.

Authors:  L F Fries; A D Montemarano; C P Mallett; D N Taylor; T L Hale; G H Lowell
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

Review 5.  Serum IgG antibodies to Shigella lipopolysaccharide antigens - a correlate of protection against shigellosis.

Authors:  Dani Cohen; Shiri Meron-Sudai; Anya Bialik; Valeria Asato; Sophy Goren; Ortal Ariel-Cohen; Arava Reizis; Amit Hochberg; Shai Ashkenazi
Journal:  Hum Vaccin Immunother       Date:  2019-05-09       Impact factor: 3.452

6.  Evaluation of the Safety, Tolerability, and Immunogenicity of an Oral, Inactivated Whole-Cell Shigella flexneri 2a Vaccine in Healthy Adult Subjects.

Authors:  Subhra Chakraborty; Clayton Harro; Barbara DeNearing; Jay Bream; Nicole Bauers; Len Dally; Jorge Flores; Lillian Van de Verg; David A Sack; Richard Walker
Journal:  Clin Vaccine Immunol       Date:  2016-04-04

7.  Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoids.

Authors:  D N Taylor; A C Trofa; J Sadoff; C Chu; D Bryla; J Shiloach; D Cohen; S Ashkenazi; Y Lerman; W Egan
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

8.  Serum antibody to lipopolysaccharide antigens of Shigella species among U.S. military personnel deployed to Saudi Arabia and Kuwait during Operations Desert Shield and Desert Storm.

Authors:  K C Hyams; J D Malone; A L Bourgeois; R Hawkins; T L Hale; J R Murphy
Journal:  Clin Diagn Lab Immunol       Date:  1995-11

9.  Immunoglobulin subclass distribution and dynamics of Shigella-specific antibody responses in serum and stool samples in shigellosis.

Authors:  D Islam; B Wretlind; M Ryd; A A Lindberg; B Christensson
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

10.  Epidemic spread of Shigella sonnei shigellosis and evidence for development of immunity among children attending day-care centers in a communal settlement (Kibbutz).

Authors:  Y Lerman; M Yavzori; R Ambar; I Sechter; M Wiener; D Cohen
Journal:  J Clin Microbiol       Date:  1994-04       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.